Related Experiment Video

Updated: Aug 8, 2026

Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro
14:18

Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro

Published on: October 13, 2023

[Anti-inflammatory action of myoinositol in renal insufficiency]

Jacek Rysz1, Piotr Bartnicki, Robert Błaszczak

  • 1Uniwersytet Medyczny w Lodzi, Uniwersytecki Szpital Kliniczny Nr 2. rb72@interia.pl

Polski Merkuriusz Lekarski : Organ Polskiego Towarzystwa Lekarskiego
|May 20, 2006
PubMed
Abstract

Insights

Myo-inositol at concentrations found in uremic blood serum significantly reduced inflammatory mediator release from peripheral blood mononuclear cells (PBMNCs). This suggests potential anti-inflammatory effects of myo-inositol in chronic kidney disease patients.

Area of Science:

  • Biochemistry
  • Immunology
  • Nephrology

Context:

  • Chronic kidney disease (CKD) is associated with systemic inflammation.
  • Uremic patients exhibit altered levels of various metabolites, including myo-inositol.
  • Peripheral blood mononuclear cells (PBMNCs) play a key role in inflammatory responses.

Purpose:

  • To investigate the in vitro effect of myo-inositol on the release of prostaglandin E2 (PGE2) and leukotriene B4 (LTB4) from PBMNCs.
  • To compare the effects of myo-inositol at concentrations relevant to healthy individuals and uremic patients.

Summary:

  • Peripheral blood mononuclear cells (PBMNCs) from 10 uremic patients and 10 healthy controls were stimulated in vitro.
  • PBMNCs were incubated with myo-inositol at 30, 300, and 600 micromol/l.
  • Release of PGE2 and LTB4 was significantly lower at 600 micromol/l myo-inositol (uremic concentration) compared to 30 micromol/l (normal concentration) in both groups.

Impact:

  • Myo-inositol at uremic concentrations may possess anti-inflammatory properties.
  • These findings suggest a potential therapeutic role for myo-inositol in managing inflammation associated with chronic kidney disease.
  • Further research is warranted to explore the clinical application of myo-inositol in uremic patients.

More Related Videos

Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis04:37

Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis

Published on: April 25, 2025

Related Concept Videos

Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Acute Kidney Injury I: Introduction01:22

Acute Kidney Injury I: Introduction

Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...